Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | CHUK | O15111 | 1/20 | 0.41 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.41 |
| ▸ | PRKCI | P41743 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 3/20 | 0.38 |
| ▸ | JAK1 | P23458 | 3/20 | 0.38 |
| ▸ | TYK2 | P29597 | 2/20 | 0.38 |
| ▸ | CIT | O14578 | 8/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | CCNK | O75909 | 1/20 | 0.37 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.37 |
| ▸ | NEK1 | Q96PY6 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27282776 | 1.00 | IKBKB (0.41) | IKBKBCHUKNUDT1PRKCIJAK2 | |
| SCHEMBL29862485 | 0.95 | IKBKB (0.41) | IKBKBCHUKNUDT1PRKCIJAK2 | |
| SCHEMBL27282771 | 0.95 | IKBKB (0.41) | IKBKBCHUKNUDT1PRKCIJAK2 | |
| SCHEMBL27282697 | 0.92 | MAPK14 (0.40) | IKBKBCHUKPRKCICITMAPK14 | |
| SCHEMBL29862349 | 0.92 | MAPK14 (0.40) | IKBKBCHUKPRKCICITMAPK14 | |
| SCHEMBL27282796 | 0.91 | PRKCI (0.44) | IKBKBCHUKNUDT1PRKCIJAK2 | |
| SCHEMBL29862760 | 0.91 | PRKCI (0.44) | IKBKBCHUKNUDT1PRKCIJAK2 | |
| SCHEMBL27282729 | 0.89 | JAK2 (0.44) | IKBKBCHUKNUDT1PRKCIJAK2 | |
| SCHEMBL29863058 | 0.89 | IKBKB (0.41) | IKBKBCHUKNUDT1PRKCIJAK2 | |
| SCHEMBL27282766 | 0.89 | IKBKB (0.41) | IKBKBCHUKNUDT1PRKCIJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217969-A1 | SUBSTITUTED PYRROLE CARBOXAMIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2024-07-04 | — | — | US | disclosed |
| EP-4313971-A1 | SUBSTITUTED PYRROLE CARBOXAMIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2024-02-07 | — | — | EP | disclosed |
| CN-117157289-A | Substituted pyrrolecarboxamides, process for their preparation and their use as kinase inhibitors | 内尔维亚诺医疗科学公司 | 2023-12-01 | — | — | CN | disclosed |
| WO-2022207404-A1 | SUBSTITUTED PYRROLE CARBOXAMIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2022-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217969-A1 | SUBSTITUTED PYRROLE CARBOXAMIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | CDC7, CDK7, CDK17 | IKBKB 480/4885CHUK 188/4885NUDT1 2057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.